Page last updated: 2024-12-08

jmv 179

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

JMV 179: cholecystokinin receptor antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID164107
MeSH IDM0191065

Synonyms (10)

Synonym
jmv 179
119386-87-7
l-aspartic acid, n-(n-(n-(n-(n-(n-((1,1-dimethylethoxy)carbonyl)-o-sulfo-l-tyrosyl)-l-norleucyl)glycyl)-d-tryptophyl)-l-norleucyl)-, 1-(2-phenylethyl) ester
tert-butoxycarbonyl-sulfo-tyrosyl-norleucyl-glycyl-tryptophyl-norleucyl-aspartic acid phenethyl ester
jmv-179
tert butoxycarbonyl-sulfo-tyrosyl-norleucyl-glycyl-tryptophyl-norleucyl-aspartic acid phenethyl ester
boc-tyr(so3h)-nle-gly-trp-nle-asp-o-ch2-ch2-c6h5
(6s,9s,15r,18s,21s)-15-((1h-indol-3-yl)methyl)-9,18-dibutyl-2,2-dimethyl-4,7,10,13,16,19-hexaoxo-21-(phenethoxycarbonyl)-6-(4-(sulfooxy)benzyl)-3-oxa-5,8,11,14,17,20-hexaazatricosan-23-oic acid
(3s)-3-[[(2s)-2-[[(2r)-3-(1h-indol-3-yl)-2-[[2-[[(2s)-2-[[(2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-(4-sulfooxyphenyl)propanoyl]amino]hexanoyl]amino]acetyl]amino]propanoyl]amino]hexanoyl]amino]-4-oxo-4-(2-phenylethoxy)butanoic acid
AKOS040745896

Research Excerpts

Actions

ExcerptReferenceRelevance
"JMV 179 tended to increase the latency of the passive avoidance response upon retention testing at the 24th hour but not on the 7th day after training."( Behavioural effects of two cholecystokinin analogues: JMV 236 and JMV 179.
Hadjiivanova, C; Kehayov, R; Martinez, J; Petkov, VV, 1994
)
1.25
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's6 (85.71)18.2507
2000's1 (14.29)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]